Avidity Biosciences Inc (RNA)
50.00
-2.55
(-4.85%)
USD |
NASDAQ |
Nov 14, 16:00
49.98
-0.02
(-0.04%)
After-Hours: 20:00
Avidity Biosciences Revenue (Quarterly): 2.045M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 2.045M |
| March 31, 2024 | 3.543M |
| December 31, 2023 | 2.193M |
| September 30, 2023 | 2.818M |
| June 30, 2023 | 2.316M |
| March 31, 2023 | 2.233M |
| December 31, 2022 | 2.769M |
| September 30, 2022 | 2.482M |
| June 30, 2022 | 2.178M |
| March 31, 2022 | 1.795M |
| December 31, 2021 | 1.852M |
| Date | Value |
|---|---|
| September 30, 2021 | 2.163M |
| June 30, 2021 | 2.607M |
| March 31, 2021 | 2.704M |
| December 31, 2020 | 2.142M |
| September 30, 2020 | 1.746M |
| June 30, 2020 | 1.541M |
| March 31, 2020 | 1.358M |
| December 31, 2019 | 1.445M |
| September 30, 2019 | 0.65M |
| June 30, 2019 | 0.224M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.358M
Minimum
Mar 2020
3.543M
Maximum
Mar 2024
2.207M
Average
2.178M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Sarepta Therapeutics Inc | 467.17M |
| Natera Inc | 413.35M |
| Entrada Therapeutics Inc | 19.57M |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Catalyst Pharmaceuticals Inc | 128.70M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -70.79M |
| Total Expenses (Quarterly) | 84.67M |
| EPS Diluted (Quarterly) | -0.65 |
| Enterprise Value | 4.856B |
| Profit Margin (Quarterly) | -3.46K% |
| Earnings Yield | -5.90% |
| Normalized Earnings Yield | -5.900 |